Pharmacokinetics of ipriflavone and metabolites after oral administration of a corn-oil suspension relative to the osteofix tablet

American Journal of Therapeutics

Volumn 4, Issue 7-8, 1997, Pages 229-238

  Rohatagi, Shashank ^a   Barrett, Jeffrey S ^a,b   Sawyers, William ^a   Yu, Kathy ^a   Morales, Richard J ^a  

^a Somerset Pharmaceuticals   (United States)

^b DUPONT COMPANY   (United States)

Author keywords

Ipriflavone; Pharmacokinetics; Suspension; Tablet

Indexed keywords

CORN OIL; DRUG METABOLITE; IPRIFLAVONE; ISOFLAVONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSPENSION; TABLET;

EID: 0030750440     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199707000-00003     Document Type: Article

References (19)

1. Brandi ML: Flavonoids; biochemical effects and therapeutic applications. Bone Miner 1992;19(suppl):S3-S14.
2. Yoshida K, Tsukomoto T, Torii H, et al.: Disposition of ipriflavone (TC-80) in rats and dogs. Radioisotopes 1985; 34:618-623.
3. Yamazaki I, Shino A, Shimuzu Y, et al.: Effect of ipriflavone on glucocorticoid-induced osteoporosis in rats. Life Sci 1986;951-958.
4. Yamazaki I, Shino A, Tsukuda R: Effect of ipriflavone on osteoporosis induced by overactemy in rats. J Bone Miner Metab 1986;3:205-210.
5. Shino A, Mutsuo T, Tsuda M, et al.: Effect of ipriflavone on bone and mineral metabolism in streptozotocin diabetic rats. J Bone Miner Metab 1986;3:27-37.
6. Tsuda M, Kitazaki T, Ito T, Fujita T: The effects of ipriflavone (TC-80) on the bone resorption in tissue culture. J Bone Miner Res 1987;1:207-211.
7. Benvenuti S, Tanini A, Frediani U, et al.: Effects of iprifalvone and its metabolites on a clonal oesteoblastic cell line. J Bone Miner Res 1991;6:987-995.
8. Brandi ML, Gennari C: Ipriflavone: new insights into its mechanism of action on bone remodelling. Calcif Tissue Int 1993;52:151-152.
9. Levai F, Szatmari I: The metabolism of ipriflavone. Acta Pharm Hung 1995;65/6:215-218.
10. Saito AM: Pharmacokinetic study of ipriflavone (TC-80) by oral administration in healthy male volunteers. Jpn Pharm Ther J 1985;13:7223-7233.
11. Sato T, Koite T, Hamada A, et al: Pharmacokinetics of ipriflavone tablets in long-term administration to patients with osteoporosis. Jpn Pharm Ther J 1986;14:7630-7634.
12. Yoshida K, Tsukomoto T, Torii H, et al.: Metabolism of ipriflavone (TC-80) in rats. Radioisotopes 1985;34:612-617.
13. Osteofix Pharmacokinetics A study report, Italy: Chiesi Farmaceutici SPA (1992).
14. Suda A: Effect of parathyroid hormone on the parietal bones of rats, and effects of ipriflavone. J Bone Miner Metab 1987;5:51-56.
15. Levai F, Szatmari I: The pharmacokinetics of ipriflavone. Acta Pharm Hung 1995;65/6:219-222.
16. Monostory K, Vereczkey L: Interaction of theophylline and ipriflavone at the P450 level. Eur J Drug Met Pharmacokin 1995;20(1):43-47.
17. Yu K, Sawyers W, DeWitt K, et al.: The analysis of ipriflavone and its five metabolites in human plasma by HPLC. Pharm Res 1995;12(suppl):S-46.
18. Brandi MI: Ipriflavone influences the osteoblastic phenotype in vitro. Osteoporos Int 1993;3(Suppl) S226-S229.
19. Foutilan JB: Pharmacokinetics and metabolism of ipriflavone in humans. Osteoporisis APS, 3, 2151-2155, 1990.